Bexagliflozin found as effective as dapagliflozin for glycemic control in diabetes: Study
China: A 24-week, phase 3 trial has shed light on the safety and efficacy of bexagliflozin versus dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus (T2D). Bexagliflozin and dapagliflozin are sodium-glucose cotransporter-2 (SGLT2) inhibitors. According to the study, bexagliflozin, when used in Chinese patients on metformin, showed nearly identical […]